South San-Francisco-based Structure’s obesity pill results rival Novo, Lilly treatments
Published on March 17, 2026.
Structure Therapeutics' shares rose after more data revealed that its experimental weight-loss pill, aleniglipron, could rival new oral treatments from Novo Nordisk A/S and Eli Lilly & Co. Patients on the once-daily pill lost about 15% of their body weight after 44 weeks, while those given a placebo added a few pounds. The drug's efficacy appears to be highly competitive, according to BMO Capital Markets analyst Evan Seigerman. The news led Structure's shares to rise by 7.7%. The company is one of several companies vying for a piece of the obesity market, which is expected to reach $100 billion by 2030.
Related Articles
JCPS school psychologists defend positions in face of budget cuts
Jefferson County Public Schools are considering 13 contract days for school psychologists to cut costs and prevent service delays, despite concerns over staff shortages and service cuts.
Dollars & Sense: Retailers rethink healthcare after a string of failures
Retailers like Amazon and Costco are shifting focus on integrating everyday shopping with healthcare, despite past failures, focusing on narrower, cost-effective solutions like Costco’s Sesame Care program.
If states ban fluoride, more kids will get cavities and Medicaid costs could soar, study finds
A CareQuest analysis reveals that if five states ban fluoride in drinking water, the cost of treating children with early tooth decay could rise significantly, potentially leading to significant Medicaid costs.